Enhanced Combined 177Lu-DOTATATE and 90Y-DOTATATE Treatment of Patients with Metastatic Neuroendocrine Tumors Refractory to Conventional Therapy: An Ongoing Study.

#358

Introduction: Neuroendocrine tumors (NETs) over-express somatostatin receptors (SRs) and the efficacy of peptide receptor radionuclide therapy (PRRT) with somatostatin analogues labeled with high activities of ß-emitting radioisotopes have been reported.

Aim(s): To further evaluate efficacy and toxicity of tandem treatment with 6 cycles of radiolabeled DOTATATE alternating 177Lu and 90Yin patients with metastasised NETs expressing SRs refractory to conventional therapies after our group obtained satisfactory results in a previous parallel study with 4 cycles.

Materials and methods: Treatment of 40 patients with 6 cycles alternating 177Lu-DOTATATE (5.55GBq) and 90Y-DOTATATE (2.6GBq).Dosimetry is performed following administration of 177Lu-DOTATATE. Hematological and renal toxicities are graded according to WHO toxicity grading scales and treatment efficacy evaluated using RECIST criteria.

Conference:

Presenting Author:

Authors: Mallia A, Seregni E, Maccauro M, Chiesa C, Coliva A,

Keywords: Neuroendocrine tumors,peptide receptor radionuclide therapy. Study is partially supported by a grant from the Min.of Health (5 per mille) and Italian Association of Cancer (AIRC).,